Free Trial

Leerink Partners Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Palvella Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Leerink Partners initiated coverage of Palvella Therapeutics with an “outperform” rating and a $228 price target, implying about 49.5% upside from the stock’s current price.
  • Analyst sentiment is broadly positive: the stock has a consensus “Buy” rating and an average price target of $214.86, though one firm rates it a sell.
  • Palvella reported quarterly loss per share of $1.70, beating the $1.78 loss analysts expected. Insiders sold 67,306 shares worth about $9.8 million over the past 90 days.
  • MarketBeat previews top five stocks to own in December.

Investment analysts at Leerink Partners started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) in a research note issued on Monday, Briefing.com reports. The brokerage set an "outperform" rating and a $228.00 price target on the stock. Leerink Partners's price objective points to a potential upside of 49.53% from the stock's current price.

A number of other research firms have also commented on PVLA. William Blair initiated coverage on Palvella Therapeutics in a report on Friday, October 16th. They issued an "outperform" rating for the company. Raymond James Financial set a $226.00 price target on Palvella Therapeutics in a report on Friday, October 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Oppenheimer increased their price objective on Palvella Therapeutics from $210.00 to $232.00 and gave the company an "outperform" rating in a research report on Friday, November 6th. Finally, Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $214.86.

Read Our Latest Report on Palvella Therapeutics

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $152.48 on Monday. Palvella Therapeutics has a 12-month low of $72.22 and a 12-month high of $179.95. The company has a market cap of $2.23 billion, a P/E ratio of -27.72 and a beta of -0.21. The company's fifty day simple moving average is $143.56 and its two-hundred day simple moving average is $129.97.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.08. Analysts predict that Palvella Therapeutics will post -6.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the company's stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the completion of the transaction, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This represents a 66.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Martini sold 6,250 shares of the company's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $166.98, for a total value of $1,043,625.00. Following the completion of the transaction, the insider owned 4,266 shares of the company's stock, valued at $712,336.68. The trade was a 59.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,306 shares of company stock valued at $9,800,571 in the last 90 days. 17.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of PVLA. Marshall Wace LLP increased its holdings in Palvella Therapeutics by 11,463.8% in the 3rd quarter. Marshall Wace LLP now owns 329,799 shares of the company's stock valued at $45,489,000 after acquiring an additional 326,947 shares during the last quarter. Voya Investment Management LLC lifted its stake in Palvella Therapeutics by 2.8% in the 3rd quarter. Voya Investment Management LLC now owns 5,878 shares of the company's stock worth $811,000 after purchasing an additional 162 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of Palvella Therapeutics by 24.7% during the 3rd quarter. Royce & Associates LP now owns 50,509 shares of the company's stock valued at $6,967,000 after purchasing an additional 10,000 shares during the last quarter. ACT Capital Partners L.P. bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at about $3,103,000. Finally, William Blair Investment Management LLC bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at about $26,906,000. Institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company's platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Read More

Analyst Recommendations for Palvella Therapeutics (NASDAQ:PVLA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Palvella Therapeutics Right Now?

Before you consider Palvella Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.

While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines